New drug adds to arsenal against AIDS

A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.

Rilpivirine, marketed by pharmaceutical firm Tibotec under the brand name of Edurant, is both safe and effective and its side effects are fewer and less severe compared with the widely-used efavirenz, or Sustiva, they say.

Combination therapy for new commonly entails giving either efavirenz or nevirapine in conjunction with drugs of a separate class in order to attack the (HIV) from different angles.

Efavirenz and nevirapine are equally effective at suppressing HIV but can cause severe side effects, which is why there has been a search for a substitute drug in their class.

The two studies report on data from two trials carried out among nearly 1,400 patients in 21 countries.

Rilpivirine, a so-called second generation antiretroviral, was approved for combination therapy in May by the (FDA).

The study appears in the runup to a four-day medical conference, starting in Rome on Sunday, on the state of the HIV/AIDS pandemic.

Acquired immune deficiency syndrome (AIDS) has claimed some 30 million lives since the first recorded cases emerged in June 1981. At least 33 million people are living with HIV, according to UN estimates for 2009.

Related Stories

US approves new HIV drug

date May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

Recommended for you

Austrian magazine printed with HIV blood

date 14 hours ago

An Austrian men's magazine has printed its latest edition using blood from people who are HIV-positive in order to counter the "stigma" often attached to the virus that causes AIDS, its chief editor said Tuesday.

Scientists 'un-can' the HIV virus

date May 04, 2015

If the human immunodeficiency virus (HIV) is a bit like a hermetically sealed tin can no one has yet been able to break open, the good news is that researchers at the CHUM Research Centre, affiliated with ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.